3D liver analysis software in complex hepatocellular liver cancer resection

Abstract

Abstract: Objective To analyze the value of 3D liver analysis software in complex hepatocellular cancer resection.Methods 64 patients with hepatocellular cancer admitted to our hospital between May 2020 and March 2023 were divided into a control group (n=32) and an observation group (n=32) according to the random number table method. The control group was examined preoperatively by ultrasound and the observation group was examined preoperatively using 3D liver analysis software.Results Operating time, intraoperative bleeding, virtual liver resection volume, actual resected liver volume, residual liver volume, and standard residual liver volume in the observation group [(311.2±72.5) min, (310.2±128.6) mL, (993.6±211.3) mL, (981.2±206.5) mL, (689.5±81.6) mL, (46.5± (7.6) %] were better than those in the control group [(352.9±85.6) min, (406.8±225.6) mL, (1171.5±245.6) mL, (1141.6±216.5) mL, (625.6±58.9) mL, (41.2±6.5) %, P<0.05]. The levels of methemoglobin, glutathione, ghrelin and bilirubin in the observation group [(116.5±7.8) ng/mL, (22.8±8.6) IU/L, (30.65±4.6) IU/L, (6.8±2.9) μmol/L] were better than those in the control group [(215.3±6.1) ng/mL, (35.2±11.5) IU/L, (34.62±5.3) IU/L, (13.1±2.4) μmol/L, P<0.05]. The ability of daily living (ADL) score of the observation group at 1-6 months after surgery was 86.8 ± 2.9, significantly higher than that of the control group [(61.1±2.4), P<0.05]. The overall incidence of complications such as bleeding, infection, biliary fistula and liver failure in the observation group (9.4%) was significantly lower than that in the control group [(56.3%), P<0.05].Conclusion Applying 3D liver analysis software to complex hepatocyte resection not only optimizes surgical and clinical indices, but also reduces complications and improves daily survival of patients, which is worthy of clinical application.

Key words: 3D Liver analysis software, Complex type, Hepatocellular liver cancer, Resection

CHENG Xiao-jie, PENG Xing-hua, GE Hai-jiang, CHENG Hai-chao, ZHANGMing, LI Zhi-feng. 3D liver analysis software in complex hepatocellular liver cancer resection[J]. Chinese Hepatolgy, 2025, 30(3): 352-355.

References

[1] 李相成, 李长贤, 张嘉伟, 等. 多模式治疗肝细胞肝癌的共识与争议[J]. 中国实用外科杂志,2018,38(1):41-44.
[2] Vogel A, Meyer T, Sapisochin G, et.al. Hepatocellular carcinoma[J]. Lancet,2022,400(10360):1345-1362.
[3] Yang J D, Hainaut P, Gores G J, et.al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
[4] Sim H W, Knox J. Hepatocellular carcinoma in the era of immunotherapy[J]. Curr Probl Cancer,2018,42(1):40-48.
[5] Vibert E, Schwartz M, Olthoff K M. Advances in resection and transplantation for hepatocellular carcinoma[J]. J Hepatol,2020,72(2):262-276.
[6] Hack S P, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation[J]. Future Oncol,2020,16(15):975-989.
[7] Singal A G, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends[J]. J Hepatol,2020,72(2):250-261.
[8] Goehler A, Harry Hsu T M, Lacson R, et al. Three-dimensional neural network to automatically assess liver tumor burden change on consecutive liver mris[J]. J Am Coll Radiol,2020,17(11):1475-1484.
[9] 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志,2017,33(8):1419-1431.
[10] Jänne P A, Baik C, Su W C, et al. Efficacy and safety of patritumab deruxtecan (her3-dxd) in egfr inhibitor-resistant, egfr-mutated non-small cell lung cancer[J]. Cancer Discov,2022,12(1):74-89.
[11] 李海东, 刘月伟, 王泳, 等. 综合康复治疗对脑部恶性肿瘤患者术后肢体功能及生活质量的影响[J]. 癌症进展,2019,17(13):1605-1608.
[12] Lee T K, Guan X Y, Ma S. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications[J]. Nat Rev Gastroenterol Hepatol,2022,19(1):26-44.
[13] Cheng K, Cai N, Zhu J, et al. Tumor-associated macrophages in liver cancer: from mechanisms to therapy[J]. Cancer Commun (Lond),2022,42(11):1112-1140.
[14] El Amrousy D, Elgendy E, Awad M E, et al. Three-dimensional speckle tracking echocardiography for early detection of left ventricular dysfunction in children with non-alcoholic fatty liver diseases[J]. Cardiol Young,2021,31(4):562-567.
[15] Chen C Y, Tsou Y F, Yeh Y T, et al. Advanced preoperative three-dimensional planning decreases the surgical complications of using large-for-size grafts in pediatric living donor liver transplantation[J]. J Pediatr Surg,2022,57(7):1210-1214.
[16] Li A, Tang R, Rong Z, et al. The use of three-dimensional printing model in the training of choledochoscopy techniques[J]. World J Surg,2018,42(12):4033-4038.
[17] El Razaky O, El Amrousy D, Elrifaey S, et al. Three-dimensional speckle tracking echocardiography: is it the magic wand in the diagnosis of subclinical myocardial dysfunction in children with type 1 diabetes mellitus[J]. Echocardiography,2018,35(10):1657-1663.
[18] Jeon H J, Jeong S, Choi H S, et al. A comparative study on aqueous chitosan solution and various submucosal injection fluids using a three-dimensional sensor[J]. Gut Liver,2021,15(2):217-224.
[19] 龚梅林, 刘丽丽, 冉雄, 等. 3D肝脏分析软件用于复杂型肝癌切除术前评估[J]. 中国医学影像技术,2022,38(6):884-887.